Kingmed Diagnostics(SH:603882)2021-04-19 16:00Financial Performance - Net profit attributable to shareholders surged by 1,023.12% to CNY 538,090,179.47, driven by significant revenue growth[7] - Operating revenue reached CNY 2,678,827,943.92, marking a 128.81% increase year-on-year[7] - Basic earnings per share increased to CNY 1.16, up 1,060.00% from CNY 0.10 in the same period last year[7] - The total comprehensive income for Q1 2021 was CNY 555,564,174.63, compared to CNY 55,556,088.04 in Q1 2020, marking an increase of 900.1%[35] - The net profit attributable to the parent company surged to RMB 538,090,179.47, a remarkable increase of 1023.12% from RMB 47,910,124.90 in the previous year[17] - The net profit for Q1 2021 was ¥553,395,235.65, up from ¥55,207,352.73 in Q1 2020, indicating an increase of 900.5%[34] Asset and Liability Growth - Total assets increased by 19.32% to CNY 7,921,715,714.88 compared to the end of the previous year[6] - The total liabilities for lease increased to RMB 230,878,686.89, reflecting the implementation of new leasing standards[16] - The company's total liabilities increased to CNY 3,322,133,838.69 from CNY 2,762,730,952.25, reflecting a rise in operational scale[24] - The total assets as of March 31, 2021, reached CNY 7,921,715,714.88, up from CNY 6,639,312,967.40 at the end of 2020, indicating strong asset growth[23] - The total liabilities as of March 31, 2021, were ¥534,152,231.47, down from ¥733,490,800.09 at the end of 2020, indicating a decrease of 27.3%[29] Cash Flow and Liquidity - Net cash flow from operating activities was CNY 160,605,600.21, a turnaround from a negative cash flow of CNY -117,839,591.24 in the same period last year, representing a 236.29% increase[6] - Cash received from sales and services amounted to CNY 1,916,148,570.07, representing a 114.07% increase compared to CNY 895,114,529.05 in the previous period, primarily due to business growth[19] - The cash flow from operating activities showed a substantial increase, indicating improved liquidity and operational efficiency[18] - The cash flow from operating activities generated a net amount of CNY 160,605,600.21, a turnaround from a net outflow of CNY 117,839,591.24 in the previous year[42] - The net cash outflow from investing activities was CNY -199,689,374.79, compared to CNY -119,800,693.18 in Q1 2020, indicating an increase in investment activities[42] Expense Management - The gross profit margin improved from 37.24% to 47.10%, an increase of 9.86 percentage points due to scale effects and project structure optimization[7] - Sales expense ratio decreased from 14.74% to 11.35%, while management expense ratio fell from 9.27% to 7.12%, resulting in a combined decrease of 5.55 percentage points[7] - The company reported a significant rise in research and development expenses, totaling RMB 106,417,377.03, which is a 53.91% increase year-over-year[17] - The company's sales expenses rose by 76.10% to RMB 303,992,901.79, driven by increased business activities[17] - Cash paid for employee compensation increased by 51.56% to CNY 462,973,219.58 from CNY 305,469,496.77, reflecting a rise in workforce costs[19] Shareholder Information - The total number of shareholders reached 30,350 by the end of the reporting period[12] - The company completed a non-public offering of 3,123,698 shares on April 9, 2021, enhancing its capital base[19] - Total equity attributable to shareholders reached ¥3,787,213,437.89, with retained earnings of ¥2,298,505,027.25[50]